Responses
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
SAT0144 A Phase I Pharmacokinetic Study Comparing SB2, An Infliximab Biosimilar, And Infliximab Reference Product (Remicade®) in Healthy Subjects
Compose a Response to This Article
Other responses
No responses have been published for this article.